Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are ...

Researchers at the University of Sussex, in collaboration with scientists from different institutes worldwide, have ...

Automation, AI, and human organoids enable researchers to move away from outdated 2D cell cultures and animal models, ...

Cambridge expertise has been intrinsic to a world first – loading a complete genome onto a quantum computer. The milestone ...

The entire genome of the D-type hepatitis virus, which is transmitted through blood or bodily fluids, has been successfully ...

Afforestation—establishing forests on previously non-forested land, or where forests have not existed for a long time—is one ...

A team of scientists from NTU Singapore has developed a new biochip that, when paired with artificial intelligence, can ...

Discover how a new nanophotonic chip uses genetic markers and AI to detect diseases in minutes, potentially revolutionising ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...

As Artificial Intelligence matures from a tool into a reality, we have traded the nosy neighbor for a clinical, invisible, ...

Engineered cells are a high-value genetic asset that is key to many fields, including biotechnology, medicine, aging, and ...

At the core of these advancements lies the concept of tokenization — a fundamental process that dictates how user inputs are interpreted, processed and ultimately billed. Understanding tokenization is ...